5 biological product launched in 1999 with 4 holding the largest market share in China.
Focusing on research and commercialization of recombinant protein drugs from prokaryotic expression and mammalian cell expression.
Robust pipeline comprising of biosimilars and innovative biologics.
Manufacturing facilities complying with cGMP requirements.
Dosage forms: ampoules, vials, pre-filled syringes, etc.
Qilu Biopharmaceutical Industrial Park
Constructed in accordance with the cGMP requirements of USFDA, EMA and NMPA. Inspected and Certified by USDFDA, EU GMP and Chinese cGMP
Manufacturing facilities are available for production of:
-Mammalian cell expression products
-Prokaryotic cell expression products
-Small molecule finished formulations